Feeding Strategies Around Blood Transfusions for Necrotizing Enterocolitis
(WHEAT Trial)
Trial Summary
What is the purpose of this trial?
The WHEAT International trial is a comparative effectiveness trial exploring whether withholding enteral feeds around the time of blood transfusion in very premature infants (\<30 weeks) will reduce the occurrence of Necrotizing Enterocolitis (NEC). Currently both continued feeding and withholding feeding are approved care practices. The current study will randomize infants from Neonatal Intensive Care Units (NICUs) across Canada and the United Kingdom (UK) into one of the two care approaches (withholding or continued feeds) to determine if any significant outcomes are found.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It focuses on feeding strategies around blood transfusions for very premature infants.
What data supports the effectiveness of the treatment of withholding feeds around transfusion for necrotizing enterocolitis?
There is limited evidence suggesting that withholding feeding during blood transfusion in preterm infants may reduce the risk of developing necrotizing enterocolitis (NEC). However, current studies, including a pilot trial, do not provide strong support for this approach, and further well-designed research is needed to confirm its effectiveness.12345
Is it safe to continue or withhold feeding during blood transfusions in preterm infants?
There is limited evidence suggesting that withholding feeds during blood transfusions may reduce the risk of necrotizing enterocolitis (a serious intestinal disease) in preterm infants, but more research is needed to confirm this. Some studies found no significant difference in safety between continuing and withholding feeds, indicating that both practices might be safe, but larger studies are required for a definitive conclusion.23456
How does the feeding strategy around blood transfusions differ from other treatments for necrotizing enterocolitis?
This treatment involves withholding feeds during blood transfusions to potentially reduce the risk of necrotizing enterocolitis (NEC) in preterm infants, which is different from other treatments that do not focus on feeding timing around transfusions. While some studies suggest this approach might lower NEC risk, more research is needed to confirm its effectiveness.12347
Research Team
Jon Dorling, MD
Principal Investigator
Princess Anne Hospital, UK
Chris Gale, MD
Principal Investigator
Imperial College London, UK
Balpreet Singh, MD
Principal Investigator
IWK Health, Canada
Eligibility Criteria
This trial is for very premature infants born before 30 weeks of gestation. It's not suitable for babies with major GIT abnormalities, those whose parents opt out, or who have had a blood transfusion with feeds or a previous episode of NEC/SIP before their first transfusion.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Infants are randomized to either withhold or continue enteral feeds around blood transfusion until 34(+6) weeks gestational age
Follow-up
Participants are monitored for safety and effectiveness after treatment, including NEC, ROP, severe brain injury, and other outcomes
Treatment Details
Interventions
- Continued feeds around transfusion (Behavioural Intervention)
- Withholding feeds around transfusion (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
IWK Health Centre
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Imperial College London
Collaborator